Categories
Change Password!
Reset Password!
As there has been an substantial
reasearch about osteoporosis in women; this study could help
formulate preoperative screening recommendations, considerations of
teriparatide treatment and its utility in spine fusion procedure in men.
A person affected from osteoporosis suffers from weak and
brittle bones easily prone to fractures that result from mechanical forces that
would not ordinarily result in fracture. Women are about four times as likely
as men to have the ill-condition.
Teriparatide is a systemically administered peptide
hormone. It is FDA-approved for osteoporosis treatment in postmenopausal women
or other populations who are prone to high risk for fracture.
The PubMed literature review mentioned in this study was
executed to review preclinical and clinical evidence for the use of
teriparatide in osteoporotic patients undergoing spine fusion surgery.
Teriparatide increases spinal fusion rates as per the preclinical studies in
animal models. In few early clinical studies,it was found that teriparatide
both increases spinal fusion rates and decreases hardware loosening in the
setting of postmenopausal osteoporosis.
In future, on-going additional trials will help compose
preoperative screening recommendations. It will also help to determine the
optimal duration of preoperative and postoperative teriparatide treatment, and
investigate its utility in men.
World neurosurgery
Evidence for Use of Teriparatide in Spinal Fusion Surgery in Osteoporotic Patients
Navjot Chaudhary et al.
Comments (0)